Cardio Diagnostics (CDIO) vs VolitionRX (VNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
VolitionRX is the larger company by market cap ($6.6 million vs $5.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CDIO | VNRX |
|---|---|---|
| Share price | $1.86 | $0.2193 |
| Market cap | $5.51M | $6.59M |
| 1-day change | -5.42% | -2.96% |
| EPS (TTM) | $-2.91 | $-3.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.91 | $12.80 |
| 52-week low | $0.97 | $0.217 |
| Distance from 52-week high | -76.45% | -98.29% |
| Average volume | 55.63K | 8.46M |
| Shares outstanding | 2.96M | 30.06M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CDIO vs VNRX FAQ
Which is bigger, Cardio Diagnostics or VolitionRX?
VolitionRX (VNRX) is larger, with a market capitalization of $6.59M compared with $5.51M for Cardio Diagnostics (CDIO).
Are Cardio Diagnostics and VolitionRX in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.